Vaccines chief hints at sidelining Astrazeneca

A senior official in the European Medicines Agency (EMA) has suggested abandoning Astrazeneca’s coronavirus vaccine for all age groups where alternatives are available.

Marco Cavaleri, head of vaccine strategy, said that due to “very rare” blood clots, countries such as France and Germany are considering the move as MRNA jabs like Pfizer and Moderna become more available. Even the Johnson & Johnson, which uses the same technology as Astrazeneca, could be preferential he said.